Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Apalutamide

FDA-approved product (tablet, oral), marketed as Apalutamide, Erleada.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Apalutamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Metastatic prostate cancer
  • Neoplasm
  • Prostate adenocarcinoma
  • Prostate cancer
  • Prostate carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Anti-androgens
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis67.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Apalutamide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Apalutamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer

    NCT04409288 · start 2020-07-20

    Registered record
    Registry ID
    NCT04409288
    Conditions
    Prostate Cancer
    Interventions
    Apalutamide; Enzalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2020-07-20
    Completion
    2023-10-16
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionApalutamide; Enzalutamide
    PhasePhase 3
    Registry statusTerminated

  • Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients

    NCT04115007 · start 2020-06-23

    Registered record
    Registry ID
    NCT04115007
    Conditions
    Oligometastatic Hormone Sensitive Prostate Cancer
    Interventions
    Stereotactic Body Radiotherapy (SBRT) + Standard of care; Standard of care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2020-06-23
    Completion
    2031-02-28
    Enrolment
    550

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOligometastatic Hormone Sensitive Prostate Cancer
    InterventionStereotactic Body Radiotherapy (SBRT) + Standard of care; Standard of care
    PhasePhase 3
    Registry statusActive not recruiting

  • Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer

    NCT04421222 · start 2020-06-23

    Registered record
    Registry ID
    NCT04421222
    Conditions
    Prostate Cancer
    Interventions
    EPI-7386 (QD); EPI-7386 (BID); Abiraterone acetate; Apalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2020-06-23
    Completion
    2024-12-03
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionEPI-7386 (QD); EPI-7386 (BID); Abiraterone acetate; Apalutamide
    PhasePhase 1
    Registry statusTerminated

  • Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer

    NCT04267887 · start 2020-05-11

    Registered record
    Registry ID
    NCT04267887
    Conditions
    Castration-Sensitive Prostate Carcinoma; Metastatic Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8
    Interventions
    Abiraterone Acetate; Antiandrogen Therapy; Apalutamide; Prednisone; Computed Tomography; Bone Scan; Biospecimen Collection; Questionnaire Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-05-11
    Completion
    2030-01-01
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration-Sensitive Prostate Carcinoma; Metastatic Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8
    InterventionAbiraterone Acetate; Antiandrogen Therapy; Apalutamide; Prednisone +4 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer

    NCT03488810 · start 2020-03-10

    Registered record
    Registry ID
    NCT03488810
    Conditions
    Prostate Cancer
    Interventions
    Radiation Therapy; Apalutamide; Luteinising Hormone Releasing Hormone analog agonist (LHRHa); Non-steroidal anti-androgen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2020-03-10
    Completion
    2026-06-15
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionRadiation Therapy; Apalutamide; Luteinising Hormone Releasing Hormone analog agonist (LHRHa); Non-steroidal anti-androgen
    PhasePhase 3
    Registry statusWithdrawn

  • A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation

    NCT04104893 · start 2020-02-20

    Registered record
    Registry ID
    NCT04104893
    Conditions
    Metastatic Castration Resistant Prostate Cancer
    Interventions
    Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-02-20
    Completion
    2026-12-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration Resistant Prostate Cancer
    InterventionPembrolizumab
    PhasePhase 2
    Registry statusActive not recruiting

  • A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)

    NCT04108208 · start 2019-12-17

    Registered record
    Registry ID
    NCT04108208
    Conditions
    Prostatic Neoplasms
    Interventions
    Apalutamide; Placebo; Androgen-deprivation Therapy (ADT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-12-17
    Completion
    2026-06-05
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasms
    InterventionApalutamide; Placebo; Androgen-deprivation Therapy (ADT)
    PhasePhase 4
    Registry statusCompleted

  • A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan

    NCT04034095 · start 2019-07-08

    Registered record
    Registry ID
    NCT04034095
    Conditions
    Prostatic Neoplasms
    Interventions
    Androgen-deprivation Therapy (ADT); Bicalutamide; Abiraterone; Prednisolone; Docetaxel; Enzalutamide; Apalutamide
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-07-08
    Completion
    2024-08-13
    Enrolment
    979

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasms
    InterventionAndrogen-deprivation Therapy (ADT); Bicalutamide; Abiraterone; Prednisolone +3 more
    PhaseNot recorded
    Registry statusCompleted

  • An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer

    NCT03690141 · start 2018-11-27

    Registered record
    Registry ID
    NCT03690141
    Conditions
    Castrate-resistant Prostate Cancer (CRPC)
    Interventions
    eFT508
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2018-11-27
    Completion
    2020-04-27
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastrate-resistant Prostate Cancer (CRPC)
    InterventioneFT508
    PhasePhase 2
    Registry statusTerminated

  • A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer

    NCT03523442 · start 2018-08-31

    Registered record
    Registry ID
    NCT03523442
    Conditions
    Prostatic Neoplasms
    Interventions
    Apalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2018-08-31
    Completion
    2026-12-31
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasms
    InterventionApalutamide
    PhasePhase 1
    Registry statusActive not recruiting

  • Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

    NCT03436654 · start 2018-06-21

    Registered record
    Registry ID
    NCT03436654
    Conditions
    Prostate Cancer
    Interventions
    Apalutamide; Abiraterone Acetate; Prednisone; GnRH agonist/antagonist
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2018-06-21
    Completion
    2027-02-14
    Enrolment
    102

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionApalutamide; Abiraterone Acetate; Prednisone; GnRH agonist/antagonist
    PhasePhase 2
    Registry statusActive not recruiting

  • A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)

    NCT03311555 · start 2018-03-28

    Registered record
    Registry ID
    NCT03311555
    Conditions
    Prostate Cancer
    Interventions
    Apalutamide; Androgen deprivation; Salvage radiation therapy; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-03-28
    Completion
    2022-12-22
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionApalutamide; Androgen deprivation; Salvage radiation therapy; Docetaxel
    PhasePhase 2
    Registry statusCompleted

  • Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

    NCT03141671 · start 2017-11-24

    Registered record
    Registry ID
    NCT03141671
    Conditions
    Prostate Cancer
    Interventions
    GnRH; Bicalutamide; Salvage radiation; Abiraterone; Prednisone; Apalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2017-11-24
    Completion
    2025-12-31
    Enrolment
    345

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionGnRH; Bicalutamide; Salvage radiation; Abiraterone +2 more
    PhasePhase 2
    Registry statusUnknown

  • Active Surveillance With or Without Apalutamide Treatment in Low Risk Prostate Cancer

    NCT03088124 · start 2017-04-28

    Registered record
    Registry ID
    NCT03088124
    Conditions
    Low Risk Prostate Cancer
    Interventions
    Apalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-04-28
    Completion
    2024-10-08
    Enrolment
    93

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLow Risk Prostate Cancer
    InterventionApalutamide
    PhasePhase 2
    Registry statusCompleted

  • Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC

    NCT02913196 · start 2016-12-30

    Registered record
    Registry ID
    NCT02913196
    Conditions
    Prostate Cancer Metastatic
    Interventions
    Apalutamide; Abiraterone acetate; Docetaxel; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-12-30
    Completion
    2025-10-15
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Metastatic
    InterventionApalutamide; Abiraterone acetate; Docetaxel; Prednisone
    PhasePhase 1
    Registry statusCompleted